IPHA

Innate Pharma S.A. Sponsored ADR (IPHA) | Rumor.io

Innate Pharma

IPHA

Attention (50-day avg)0.01%

Attention rank (50-day avg)#625

Bullish sentiment (50-day avg)97%

Price to earnings ratio-3.15

Market capitalization189.9M

Earnings per share-0.58

Dividend yield (TTM)—

Revenue (annual)2.8M

Net income (annual)-49.2M

Social

What share of all stock conversation is about IPHA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.01% +0.01	0% 0

Sep 17

Innate Pharma (IPHA) completed a €30M equity financing and reported a half-year net loss of €19.6M, improving from a year ago.
The company's cash horizon is now extended into Q1 2028, including a $75M upfront payment from Sobi and a €30M equity raise.
IPHA's pipeline includes the confirmatory Phase 3 trial for lacutamab in cutaneous T-cell lymphoma, with potential royalties and up to $505M in additional payments.

Generated by AI

Sentiment

Of the messages about IPHA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +3.13	96.64% +13.8
Bearish	—	—	0% -3.13	3.36% -13.8

Bullish· Nov 10

The FDA has cleared Innate Pharma's lead drug, Lacutamab, for Phase 3 clinical trials, which could lead to accelerated approval.
The biotechnology industry is heating up, with market capitalization of approximately $170 million and huge growth potential, driven by immuno-oncology's rapid momentum.
Analysts are raising targets toward $5, and the stock has a low market capitalization, indicating a big room for growth if data delivers.

Bearish· Sep 17

The asset's price may be artificially inflated due to market manipulation.
The company's stock has significant resistance at certain price levels, making it difficult to move past them.
There is a strong possibility of a price drop, with some individuals expecting a margin call for short sellers.

Generated by AI

Topics

Of the messages about IPHA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	1.8%	10.54%
Analysts	—	—	48.91%	44.87%
Macro	—	—	48.86%	43.96%
Earnings	—	—	0.43%	0.39%
Controversies	—	—	0%	0.12%
Technical Analysis	—	—	0%	0.13%

Analysts· Sep 17

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Innate Pharma (IPHA) and set a price target of $11.50.
Evercore ISI raised Innate Pharma's price target to $10.00 with an outperform rating.
SVB Leerink analyst Daina Graybosch maintains Innate Pharma (IPHA) with an Outperform rating and raised the price target from $7 to $9.

Announcements· Nov 10

Innate Pharma (IPHA) has received FDA clearance to proceed with the TELLOMAK 3 trial, a confirmatory Phase 3 trial of lacutamab in cutaneous T-cell lymphomas (CTCL).
The trial is expected to start in H1 2026, with a potential accelerated approval pathway, and lacutamab is the company's lead drug in the immuno-oncology space.
Market capitalization is approximately $170 million, with huge growth potential, and the FDA approval is a significant step forward for Innate Pharma's pipeline in the rare oncology space.

Technical Analysis· Sep 17

IPHA's chart is considered poor, with the author admitting to making mistakes by not stopping out earlier.
The author is holding a position in IPHA, waiting for a potential move above $9, with a strong support level at $7.80.
IPHA has broken through key levels, including $7.00 and $8.00, with the author predicting further upside to $9 and potentially $12.50.

Generated by AI

Community

Of the messages about IPHA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	7.81%	26.44%
Newcomers	—	—	92.19%	73.56%

Regulars· Aug 10

Innate Pharma has entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma, with a $75M upfront payment and potential for up to $465M in milestones payments.
The partnership includes a Phase 3 trial for lacutamab, with Innate Pharma and Sobi teaming up for the TELLOMAK-3 trial.
The deal is expected to support the full development and commercialization of lacutamab, with Innate Pharma set to receive significant payments for the license and milestones.

Newcomers· Sep 17

Innate Pharma's H1 2026 earnings report shows a cash runway to end-Q1 2028, following a €30M equity financing and a $75M upfront payment from its partnership with SOBI.
The company's pipeline, particularly the confirmatory Phase 3 trial for lacutamab, is a key focus area, with the partnership with SOBI now effective and triggering the upfront payment.
Innate Pharma's H1 2026 earnings report also highlights the company's financial situation, including a negative shareholders' equity and a decrease in cash and financial assets, which were addressed through the August placement and the Sobi upfront.

Generated by AI

News

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6d agoYahoo Finance

Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab partnership with Sobi a day earlier. The closing triggered a $75 million upfront payment. Management projects funding through the end of the first quarter of 2028, including the partnership payment and a completed equity financing […]

7d agoYahoo Finance

Innate Pharma stock maintained at Buy by H.C. Wainwright

9d agoInvesting.com

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

12d agotheglobeandmail.com

Innate Pharma Q2 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab. Chief Executive Officer Jonathan

12d agoYahoo Finance

Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip

13d agoInvesting.com

Also Discussed

Investors talking about IPHA also mention

#	Name	Attention
1	GNFT - Genfit S.A.	——
2	Zivo Bioscience Inc.ZIVO	0%0
3	Katapult Holdings Inc.KPLT	0%-0.01
4	Focus Universal Inc.FCUV	0%0
5	Corvus Pharmaceuticals Inc.CRVS	0.01%-0.01
6	LVTX - LAVA Therapeutics N.V.	——
7	DBV Technologies S.A. Sponsored ADRDBVT	0%new
8	OMQS - OMNIQ Corp.	——
9	ERYP - ERYTECH Pharma S.A.	——
10	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01

Innate Pharma S.A. Sponsored ADR

Healthcare
Biotechnology

Innate Pharma S.A. Sponsored ADR is a biotechnology company focused on developing immunotherapies for cancer patients. The company uses antibody engineering and natural killer cell-based approaches to build treatments aimed at harnessing the innate immune system, with a pipeline that includes programs for hematologic cancers and solid tumors. Its current work spans clinical-stage drug development, research collaborations, and licensing arrangements with major pharmaceutical partners, reflecting a business model centered on advancing proprietary candidates through development while leveraging partnerships to broaden its therapeutic reach. Innate Pharma operates primarily in the oncology and immunotherapy segments of the healthcare market, serving as a specialized developer of next-generation antibody-based medicines. Headquartered in Marseille, France, it maintains an international presence through research and collaboration activities that support its role in modern cancer drug development.

Website

Location

117, Avenue de Luminy

Marseille, 13009

France

Social

What share of all stock conversation is about IPHA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.01% +0.01	0% 0

Sep 17

Innate Pharma (IPHA) completed a €30M equity financing and reported a half-year net loss of €19.6M, improving from a year ago.
The company's cash horizon is now extended into Q1 2028, including a $75M upfront payment from Sobi and a €30M equity raise.
IPHA's pipeline includes the confirmatory Phase 3 trial for lacutamab in cutaneous T-cell lymphoma, with potential royalties and up to $505M in additional payments.

Generated by AI

Sentiment

Of the messages about IPHA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +3.13	96.64% +13.8
Bearish	—	—	0% -3.13	3.36% -13.8

Bullish· Nov 10

The FDA has cleared Innate Pharma's lead drug, Lacutamab, for Phase 3 clinical trials, which could lead to accelerated approval.
The biotechnology industry is heating up, with market capitalization of approximately $170 million and huge growth potential, driven by immuno-oncology's rapid momentum.
Analysts are raising targets toward $5, and the stock has a low market capitalization, indicating a big room for growth if data delivers.

Bearish· Sep 17

The asset's price may be artificially inflated due to market manipulation.
The company's stock has significant resistance at certain price levels, making it difficult to move past them.
There is a strong possibility of a price drop, with some individuals expecting a margin call for short sellers.

Generated by AI

Topics

Of the messages about IPHA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	1.8%	10.54%
Analysts	—	—	48.91%	44.87%
Macro	—	—	48.86%	43.96%
Earnings	—	—	0.43%	0.39%
Controversies	—	—	0%	0.12%
Technical Analysis	—	—	0%	0.13%

Analysts· Sep 17

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Innate Pharma (IPHA) and set a price target of $11.50.
Evercore ISI raised Innate Pharma's price target to $10.00 with an outperform rating.
SVB Leerink analyst Daina Graybosch maintains Innate Pharma (IPHA) with an Outperform rating and raised the price target from $7 to $9.

Announcements· Nov 10

Innate Pharma (IPHA) has received FDA clearance to proceed with the TELLOMAK 3 trial, a confirmatory Phase 3 trial of lacutamab in cutaneous T-cell lymphomas (CTCL).
The trial is expected to start in H1 2026, with a potential accelerated approval pathway, and lacutamab is the company's lead drug in the immuno-oncology space.
Market capitalization is approximately $170 million, with huge growth potential, and the FDA approval is a significant step forward for Innate Pharma's pipeline in the rare oncology space.

Technical Analysis· Sep 17

IPHA's chart is considered poor, with the author admitting to making mistakes by not stopping out earlier.
The author is holding a position in IPHA, waiting for a potential move above $9, with a strong support level at $7.80.
IPHA has broken through key levels, including $7.00 and $8.00, with the author predicting further upside to $9 and potentially $12.50.

Generated by AI

Community

Of the messages about IPHA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	7.81%	26.44%
Newcomers	—	—	92.19%	73.56%

Regulars· Aug 10

Innate Pharma has entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma, with a $75M upfront payment and potential for up to $465M in milestones payments.
The partnership includes a Phase 3 trial for lacutamab, with Innate Pharma and Sobi teaming up for the TELLOMAK-3 trial.
The deal is expected to support the full development and commercialization of lacutamab, with Innate Pharma set to receive significant payments for the license and milestones.

Newcomers· Sep 17

Innate Pharma's H1 2026 earnings report shows a cash runway to end-Q1 2028, following a €30M equity financing and a $75M upfront payment from its partnership with SOBI.
The company's pipeline, particularly the confirmatory Phase 3 trial for lacutamab, is a key focus area, with the partnership with SOBI now effective and triggering the upfront payment.
Innate Pharma's H1 2026 earnings report also highlights the company's financial situation, including a negative shareholders' equity and a decrease in cash and financial assets, which were addressed through the August placement and the Sobi upfront.

Generated by AI

Innate Pharma

Social

Sep 17

Bullish· Nov 10

Bearish· Sep 17

Analysts· Sep 17

Announcements· Nov 10

Technical Analysis· Sep 17

Regulars· Aug 10

Newcomers· Sep 17

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

Innate Pharma stock maintained at Buy by H.C. Wainwright

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma Q2 Earnings Call Highlights

Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip

Also Discussed

Innate Pharma S.A. Sponsored ADR

Company Information

Location

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

Innate Pharma stock maintained at Buy by H.C. Wainwright

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma Q2 Earnings Call Highlights

Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip

Also Discussed

Social

Sep 17

Bullish· Nov 10

Bearish· Sep 17

Analysts· Sep 17

Announcements· Nov 10

Technical Analysis· Sep 17

Regulars· Aug 10

Newcomers· Sep 17